These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 33482769

  • 1. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P.
    BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769
    [Abstract] [Full Text] [Related]

  • 2. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.
    Lancet Oncol; 2019 Dec 22; 20(12):1719-1729. PubMed ID: 31704134
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I.
    Lancet Oncol; 2013 Aug 22; 14(9):901-8. PubMed ID: 23867211
    [Abstract] [Full Text] [Related]

  • 4. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.
    Bukata SV, Blay JY, Rutkowski P, Skubitz K, Henshaw R, Seeger L, Dai T, Jandial D, Chawla S.
    Spine (Phila Pa 1976); 2021 Mar 01; 46(5):277-284. PubMed ID: 33038190
    [Abstract] [Full Text] [Related]

  • 5. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T.
    Ann Oncol; 2015 Oct 01; 26(10):2149-54. PubMed ID: 26205395
    [Abstract] [Full Text] [Related]

  • 6. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A.
    J Clin Pathol; 2016 Mar 01; 69(3):240-7. PubMed ID: 26338802
    [Abstract] [Full Text] [Related]

  • 7. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 8. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.
    Ann Surg Oncol; 2015 Sep 15; 22(9):2860-8. PubMed ID: 26033180
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May 15; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

  • 10. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU.
    Ann Diagn Pathol; 2020 Apr 15; 45():151479. PubMed ID: 32088577
    [Abstract] [Full Text] [Related]

  • 11. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May 15; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 12. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L, Dijkstra S, van de Sande M, Gelderblom H.
    Curr Opin Oncol; 2020 Jul 15; 32(4):332-338. PubMed ID: 32541321
    [Abstract] [Full Text] [Related]

  • 13. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
    Kerr DA, Brcic I, Diaz-Perez JA, Shih A, Wilky BA, Pretell-Mazzini J, Subhawong TK, Nielsen GP, Rosenberg AE.
    Am J Surg Pathol; 2021 Jan 01; 45(1):93-100. PubMed ID: 32773532
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
    Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H.
    Oncologist; 2019 Jul 01; 24(7):889-e421. PubMed ID: 31040253
    [Abstract] [Full Text] [Related]

  • 16. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
    Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C.
    Jpn J Clin Oncol; 2017 Nov 01; 47(11):1090-1096. PubMed ID: 29048579
    [Abstract] [Full Text] [Related]

  • 17. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A, Alaqaili SI, Ahmad SO, Bin Hazzaa I, Alharbi H.
    Gulf J Oncolog; 2019 May 01; 1(30):67-75. PubMed ID: 31242985
    [Abstract] [Full Text] [Related]

  • 18. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.
    Eur J Surg Oncol; 2018 Sep 01; 44(9):1384-1390. PubMed ID: 29650420
    [Abstract] [Full Text] [Related]

  • 19. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 Sep 01; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 20. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K.
    Histopathology; 2018 May 01; 72(6):914-922. PubMed ID: 29206281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.